ADMA Biologics, Inc.
ADMA
$20.68
$1.045.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 211.61% | 12.00% | 80.06% | 200.91% | -787.65% |
| Total Depreciation and Amortization | 0.21% | -5.23% | -3.17% | 0.24% | 0.81% |
| Total Amortization of Deferred Charges | -13.10% | 11.01% | -10.28% | -63.75% | -3.19% |
| Total Other Non-Cash Items | -2,561.63% | 11.38% | 32.94% | -92.62% | 950.31% |
| Change in Net Operating Assets | 184.58% | -291.30% | 134.59% | -780.33% | -6.66% |
| Cash from Operations | 100.64% | -45.17% | 2,157.98% | -112.60% | 46.83% |
| Capital Expenditure | -161.08% | 48.89% | 11.97% | -96.07% | -58.12% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 116.67% | 85.95% | -1,893.33% | 92.86% | -- |
| Cash from Investing | -150.46% | 53.57% | -0.13% | -67.87% | -85.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -92.22% | 1,619.34% | -67.83% | 12,762.50% | -98.72% |
| Repurchase of Common Stock | 44.39% | -67.10% | 72.01% | -626.10% | -63.94% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -21.83% | -6,935.08% | 74.98% | 96.29% | -9,473.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,169.62% | -103.58% | 812.11% | 73.57% | -295.85% |